Drug intelligence / Profile preview

bifidobacterium triple live bacteria capsules

Development stage: Unknown
Lead developer: Xinyi Pharmaceutical
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifidobacterium triple live bacteria capsules (often referred to in Chinese clinical contexts as Bifidobacterium tricell live bacteria capsules) is a probiotic combination drug containing live strains of *Bifidobacterium longum*, *Lactobacillus acidophilus*, and *Enterococcus faecalis*. It is primarily indicated for the treatment of intestinal dysbiosis and associated symptoms such as diarrhea, constipation, and abdominal distension. The product works by replenishing beneficial flora, which helps maintain the microecological balance of the gut, inhibits the growth of pathogenic bacteria, and supports immune function. Recent clinical investigations, such as those conducted at Rugao People's Hospital, are evaluating its efficacy in treating diminished ovarian reserve (DOR) and menopausal symptoms, suggesting a potential therapeutic role via the gut-ovary axis.

Brand names: PeifeikangBIFIDOBI
Other names: Bifidobacterium tricell live bacteria capsulesBifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis capsulesBifidobacterium Triple Live Bacteria Capsules

Beyond the preview

Go deeper on bifidobacterium triple live bacteria capsules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifidobacterium triple live bacteria capsules.

Explore the full profile